Navigation Links
Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Date:12/15/2009

NEW YORK, Dec. 15 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

http://www.reportlinker.com/p0168098/The-Future-of-Cardiovascular-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html

Summary

The author has released its latest research "The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis." The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global cardiovascular diseases therapeutics market. The report analyzes the markets for cardiovascular disease therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

- Annualized market data for the cardiovascular diseases therapeutics market from 2000 to 2008, forecast forward to 2015

- Analysis of the leading therapeutic segments including hypertension, dyslipidemia and thrombosis

- Analysis of the cardiovascular diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

- Market characterization of the cardiovascular diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns

- Key drivers and barriers that have a significant impact on the market

- Coverage of pipeline molecules in various phases of drug development

- Competitive benchmarking of leading companies. The key companies studied in this report are Novartis AG, Sanofi-aventis, Pfizer Inc and Merck & Co

- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global cardiovascular diseases therapeutics market

Reasons to buy

The report will aid Business Development and marketing executives strategizing their product launches. It will allow you to;

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the cardiovascular diseases therapeutics market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the cardiovascular diseases therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global cardiovascular diseases therapeutics landscape? - Identify, understand and capitalize.

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Global Cardiovascular Therapeutics Market: Scope of Research

2.1 Introduction

2.2 GBI Research Report Guidance

3 Global Cardiovascular Therapeutics Market: Market Characterization

3.1 Market Forecasts

3.2 Branded Vs Generics

3.3 Average Cost of Therapy

3.4 Volume

3.5 Usage Patterns

3.5.1 Diseased Population

3.5.2 Treatment Seeking Population

3.5.3 Diagnosis Population

3.5.4 Prescription Population

3.5.5 Usage Patterns

3.5.6 Geographical Distribution

4 Global Cardiovascular Therapeutics Market: US Market

4.1 Market Overview

4.2 Market Forecasts

4.3 Average Cost of Therapy

4.4 Volume

4.5 Usage Patterns

4.5.1 Diseased Population

4.5.2 Treatment Seeking Population

4.5.3 Diagnosis Population

4.5.4 Prescription Population

4.5.5 Usage Patterns

5 Global Cardiovascular Therapeutics Market: European Market

5.1 Market Overview

5.2 Market Forecasts

5.3 Average Cost of Therapy

5.4 Volume

5.5 Usage Patterns

5.5.1 Diseased Population

5.5.2 Treatment Seeking Population

5.5.3 Diagnosis Population

5.5.4 Prescription Population

5.5.5 Usage Patterns

6 Global Cardiovascular Therapeutics Market : Japan Market

6.1 Market Forecasts

6.2 Average Cost of Therapy

6.3 Volume

6.4 Usage Patterns

6.4.1 Diseased Population

6.4.2 Treatment Seeking Population

6.4.3 Prescription Population

6.4.4 Usage Patterns

7 Global Hypertension Therapeutics Market

7.1 Market Forecasts

7.2 Average Cost of Therapy

7.3 Volume

7.4 Usage Patterns

7.4.1 Diseased Population

7.4.2 Treatment Seeking Population

7.4.3 Diagnosis Population

7.4.4 Prescription Population

7.4.5 Usage Patterns

8 Global Dyslipidemia Therapeutics Market

8.1 Market Forecasts

8.2 Average Cost of Therapy

8.3 Volume

8.4 Usage Patterns

8.4.1 Diseased Population

8.4.2 Treatment Seeking Population

8.4.3 Diagnosis Population

8.4.4 Prescription Population

8.4.5 Usage Patterns

9 Global Thrombosis Therapeutics Market

9.1 Market Forecasts

9.2 Volume

9.3 Average Cost of Therapy

9.4 Usage Patterns

9.4.1 Diseased Population

9.4.2 Treatment Seeking Population

9.4.3 Diagnosis Population

9.4.4 Prescription Population

9.4.5 Usage Patterns

10 Global Cardiovascular Therapeutics Market: Market Drivers and Restraints

10.1 Market Drivers

10.1.1 Steady Increase in the Elderly Population

10.1.2 Stable Increase in Incidence Rates for Cardiovascular Diseases

10.1.3 Increase in Awareness Levels of Disease Progression and Etiology

10.2 Market Restraints

10.2.1 Patent Expirations and Entry of Generics Pose a Serious Problem for Primary Manufacturers

10.2.2 Reimbursement Restrictions on Drug Classes for Certain Cardiovascular Disease Drug Classes Restricts the Market Growth

11 Global Cardiovascular Therapeutics Market : Unmet Needs

12 Global Cardiovascular Therapeutics Market : Key Market Trends

12.1 Increase in Disease Incidence and Prevalence Rates

12.2 Product Pipeline

12.3 Advertising and Commercialization

12.4 Regulatory trends - Current Reimbursement Scenario

12.4.1 The Budget Impact on Drug Reimbursements

12.4.2 Reliability of Generic Formulations as a Cost Cutting Measure

13 Global Cardiovascular Therapeutics Market: Competitive Landscape

13.1 Overview

13.2 Market Share Analysis

13.3 Competitive Profiling

13.3.1 Pfizer

13.3.2 Sanofi-Aventis

13.3.3 Merck

13.3.4 Novartis

14 Global Cardiovascular Therapeutics Market: M&A Landscape

14.1 Mergers and Acquisitions

14.1.1 Overview

14.2 Licensing Agreements

14.2.1 Research Phase

14.2.2 Preclinical

14.2.3 Phase I

14.2.4 Phase PI/II

14.2.5 Phase II

14.2.6 Phase III

14.2.7 Filed

15 Global Cardiovascular Therapeutics Market : Appendix

15.1 Market Definitions

15.2 Abbreviations

15.3 Research Methodology

15.3.1 Coverage

15.3.2 Secondary Research

15.3.3 Forecasts

15.3.4 Primary Research

15.3.5 Expert Panels

15.4 Contact Us

15.5 Disclaimer

1.1 List of Tables

Table 1: Global Cardiovascular Therapeutics Market, Historical Revenues ($m), 2000-2008

Table 2: Global Cardiovascular Therapeutics Market, Revenue Forecasts ($m), 2008-2015

Table 3: Global Cardiovascular Therapeutics Market, Revenue Segmentation, 2000-2008

Table 4: Global Cardiovascular Therapeutics Market, Revenue Segmentation, 2008-2015

Table 5: Global Cardiovascular Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008

Table 6: Global Cardiovascular Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2008-2015

Table 7: Global Cardiovascular Therapeutics Market, Historical Figures for Volume, 00-08

Table 8: Global Cardiovascular Therapeutics Market, Forecasts for Volume, 2008-2015

Table 9: Global Cardiovascular Therapeutics Market, Historical Figures for Diseased Population, 2000-2008

Table 10: Global Cardiovascular Therapeutics Market, Forecasts for Diseased Population , 2008-2015

Table 11: Global Cardiovascular Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008

Table 12: Global Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015

Table 13: Global Cardiovascular Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008

Table 14: Global Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015

Table 15: Global Cardiovascular Therapeutics Market, Historical Figures for Prescription Population, 2000-2008

Table 16: Global Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2008-2015

Table 17: Global Cardiovascular Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008

Table 18: Global Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2008-2015

Table 19: US Cardiovascular Therapeutics Market, Historical Revenues ($m), 2000-2008

Table 20: US Cardiovascular Therapeutics Market, Revenue Forecasts ($m), 2008-2015

Table 21: US Cardiovascular Therapeutics Market, Historical Figures for the Average Cost of Therapy ($), 2000-2008

Table 22: US Cardiovascular Therapeutics Market, Forecasts for the Average Cost of Therapy ($), 2008-2015

Table 23: US Cardiovascular Therapeutics Market, Historical Figures for Volume, 2000-2008

Table 24: US Cardiovascular Therapeutics Market, Forecasts for Volume, 2008-2015

Table 25: US Cardiovascular Therapeutics Market, Historical Figures for Diseased Population, 2000-2008

Table 26: US Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2008-2015

Table 27: US Cardiovascular Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008

Table 28: US Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015

Table 29: US Cardiovascular Therapeutics Market, Historical Figures for Diagnosis Population(000'), 2000-2008

Table 30: US Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population(000'), 2008-2015

Table 31: US Cardiovascular Therapeutics Market, Historical Figures for Prescription Population, 2000-2008

Table 32: US Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2008-2015

Table 33: US Cardiovascular Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008

Table 34: US Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2008-2015

Table 35: European Cardiovascular Therapeutics Market, Historical Revenues ($bn), 2000-2008

Table 36: European Cardiovascular Therapeutics Market, Revenue Forecasts ($m), 2008-2015

Table 37: European Cardiovascular Therapeutics Market, Historical Figures for Average Cost of Treatment, 2000-2008

Table 38: European Cardiovascular Therapeutics Market, Forecasts for Average Cost of Treatment, 2008-2015

Table 39: European Cardiovascular Therapeutics Market, Historical Figures for Volume, 2000-2008

Table 40: European Cardiovascular Therapeutics Market, Forecasts for Volume, 2008-2015

Table 41: European Cardiovascular Therapeutics Market, Historical Figures for Diseased Population, 2000-2008

Table 42: European Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2008-2015

Table 43: European Cardiovascular Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008

Table 44: European Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015

Table 45: European Cardiovascular Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008

Table 46: European Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015

Table 47: European Cardiovascular Therapeutics Market, Historical Figures for Prescription Population, 2000-2008

Table 48: European Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2008-2015

Table 49: European Cardiovascular Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008

Table 50: European Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2008-2015

Table 51: Japan Cardiovascular Therapeutics Market, Historical Revenues ($m), 2000-2008

Table 52: Japan Cardiovascular Therapeutics Market, Revenue Forecasts ($m), 2008-2015

Table 53: Japan Cardiovascular Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008

Table 54: Japan Cardiovascular Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015

Table 55: Japan Cardiovascular Therapeutics Market, Historical Figures for Volume, 2000-2008

Table 56: Japan Cardiovascular Therapeutics Market, Forecasts for Volume, 2008-2015

Table 57: Japan Cardiovascular Therapeutics Market, Historical Figures for Diseased Population, 2000-2008

Table 58: Japan Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2008-2015

Table 59: Japan Cardiovascular Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008

Table 60: Japan Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015

Table 61: Japan Cardiovascular Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008

Table 62: Japan Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015

Table 63: Japan Cardiovascular Therapeutics Market, Historical Figures for Prescription Population, 2000-2008

Table 64: Japan Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2008-2015

Table 65: Japan Cardiovascular Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008

Table 66: Japan Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2008-2015

Table 67: Global Hypertension Therapeutics Market, Historical Revenues ($m), 2000-2008

Table 68: Global Hypertension Therapeutics Market, Revenue Forecasts ($m), 2008-2015

Table 69: Global Hypertension Therapeutics Market, Historical Figures for the Average Cost of Therapy ($), 2000-2008

Table 70: Global Hypertension Therapeutics Market, Forecast Figures for the Average Cost of Therapy ($), 2008-2015

Table 71: Global Hypertension Therapeutics Market, Historical Figures for Volume, 2000-2008

Table 72: Global Hypertension Therapeutics Market, Forecasts for Volume, 2008-2015

Table 73: Global Hypertension Therapeutics Market, Historical Figures for Diseased Population, 2000-2008

Table 74: Global Hypertension Therapeutics Market, Forecasts for Diseased Population, 2008-2015

Table 75: Global Hypertension Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008

Table 76: Global Hypertension Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015

Table 77: Global Hypertension Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008

Table 78: Global Hypertension Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015

Table 79: Global Hypertension Therapeutics Market, Historical Figures for Prescription Population, 2000-2008

Table 80: Global Hypertension Therapeutics Market, Forecasts for Prescription Population, 2008-2015

Table 81: Global Hypertension Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008

Table 82: Global Hypertension Therapeutics Market, Forecasts for Usage Patterns, 2008-2015

Table 83: Global Dyslipidemia Therapeutics Market, Historical Revenues ($m), 2000-2008

Table 84: Global Dyslipidemia Therapeutics Market, Revenue Forecasts ($m), 2008-2015

Table 85: Global Dyslipidemia Therapeutics Market, Historical Figures for the Average Cost of Therapy ($), 2000-2008

Table 86: Global Dyslipidemia Therapeutics Market, Forecast Figures for the Average Cost of Therapy ($), 2008-2015

Table 87: Global Dyslipidemia Therapeutics Market, Historical Figures for Volume, 2000-2008

Table 88: Global Dyslipidemia Therapeutics Market, Forecasts for Volume, 2008-2015

Table 89: Global Dyslipidemia Therapeutics Market, Historical Figures for Diseased Population, 2000-2008

Table 90: Global Dyslipidemia Therapeutics Market, Forecasts for Diseased Population, 2008-2015

Table 91: Global Dyslipidemia Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008

Table 92: Global Dyslipidemia Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015

Table 93: Global Dyslipidemia Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008

Table 94: Global Dyslipidemia Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015

Table 95: Global Dyslipidemia Therapeutics Market, Historical Figures for Prescription Population, 2000-2008

Table 96: Global Dyslipidemia Therapeutics Market, Forecasts for Prescription Population, 2008-2015

Table 97: Global Dyslipidemia Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008

Table 98: Global Dyslipidemia Therapeutics Market, Forecasts for Usage Patterns, 2008-2015

Table 99: Global Thrombosis Therapeutics Market, Historical Revenues ($m), 2000-2008

Table 100: Global Thrombosis Therapeutics Market, Revenue Forecasts ($m), 2008-2015

Table 101: Global Thrombosis Therapeutics Market, Historical Figures for Volume, 2000-2008

Table 102: Global Thrombosis Therapeutics Market, Forecasts for Volume, 2008-2015

Table 103: Global Thrombosis Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008

Table 104: Global Thrombosis Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015

Table 105: Global Thrombosis Therapeutics Market, Historical Figures for Diseased Population, 2000-2008

Table 106: Global Thrombosis Therapeutics Market, Forecast Figures for Diseased Population, 2008-2015

Table 107: Global Thrombosis Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008

Table 108: Global Thrombosis Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015

Table 109: Global Thrombosis Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008

Table 110: Global Thrombosis Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015

Table 111: Global Thrombosis Therapeutics Market, Historical Figures for Prescription Population, 2000-2008

Table 112: Global Thrombosis Therapeutics Market, Forecasts for Prescription Population, 2008-2015

Table 113: Global Thrombosis Therapeutics Market, Historical Figures for Usage Patterns, 2000-2008

Table 114: Global Thrombosis Therapeutics Market, Forecasts for Usage Patterns, 2008-2015

Table 115: Global Cardiovascular Therapeutics Market, Market Drivers, 2008

Table 116: Global Cardiovascular Therapeutics Market, Market Restraints, 2008

Table 117: Global Cardiovascular Therapeutics Market, Major Drug Patent Expirations, 2008-2015

Table 118: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the Research Stage, 2008-2009

Table 119: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the Pre-clinical Stage, 2008-2009

Table 120: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the PI Stage, 2008-2009

Table 121: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the PI/PII Stage, 2008-2009

Table 122: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the PII Stage, 2008-2009

Table 123: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the PIII stage, 2008-2009

Table 124: Global Cardiovascular Therapeutics Market, Licensing Agreements for Drugs in the Filed Stage, 2008-2009

1.2 List of Figures

Figure 1: Global Cardiovascular Therapeutics Market, Revenue Forecast, 2000-2015

Figure 2: Global Cardiovascular Therapeutics Market, Revenue Segmentation, 2000-2015

Figure 3: Global Cardiovascular Therapeutics Market, Average Cost of Therapy ($), 2000-2015

Figure 4: Global Cardiovascular Therapeutics Market, Volume, 2000-2015

Figure 5: Global Cardiovascular Therapeutics Market, Global Diseased Population, 2000-2015

Figure 6: Global Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015

Figure 7: Global Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015

Figure 8: Global Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2000-2015

Figure 9: Cardiovascular Therapeutics Market, Global, Forecasts for Treatment Patterns, 2000-2015

Figure 10: Global Cardiovascular Therapeutics Market, Geographical Distribution of Revenues ($bn), 2000-2015

Figure 11: US Cardiovascular Therapeutics Market, Revenue Forecasts ($bn), 2000-2015

Figure 12: US Cardiovascular Therapeutics Market, Average Cost of Therapy ($), 2000-2015

Figure 13: US Cardiovascular Therapeutics Market, Volume (million), 2000-2015

Figure 14: US Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2000-2015

Figure 15: US Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015

Figure 16: US Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015

Figure 17: US Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2000-2015

Figure 18: US Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2000-2015

Figure 19: European Cardiovascular Therapeutics Market, Revenue Forecasts ($bn), 2000-2015

Figure 20: European Cardiovascular Therapeutics Market, Forecasts for Average Cost of Treatment ($), 2000-2015

Figure 21: European Cardiovascular Therapeutics Market, Forecasts for Volume, 2000-2015

Figure 22: European Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2000-2015

Figure 23: European Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015

Figure 24: European Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015

Figure 25: European Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2000-2015

Figure 26: European Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2000-2015

Figure 27: Japan Cardiovascular Therapeutics Market, Revenue Forecasts ($bn), 2000-2015

Figure 28: Japan Cardiovascular Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2000-2015

Figure 29: Japan Cardiovascular Therapeutics Market, Forecasts for Volume, 2000-2015

Figure 30: Japan Cardiovascular Therapeutics Market, Forecasts for Diseased Population, 2000-2015

Figure 31: Japan Cardiovascular Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015

Figure 32: Japan Cardiovascular Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015

Figure 33: Japan Cardiovascular Therapeutics Market, Forecasts for Prescription Population, 2000-2015

Figure 34: Japan Cardiovascular Therapeutics Market, Forecasts for Usage Patterns, 2000-2015

Figure 35: Global Hypertension Therapeutics Market, Revenue Forecasts ($bn), 2000-2015

Figure 36: Global Hypertension Therapeutics Market, Average Cost of Therapy ($), 2000-2015

Figure 37: Global Hypertension Therapeutics Market, Volume, 2000-2015

Figure 38: Global Hypertension Therapeutics Market, Forecasts for Diseased Population, 2000-2015

Figure 39: Global Hypertension Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015

Figure 40: Global Hypertension Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015

Figure 41: Global Hypertension Therapeutics Market, Forecasts for Prescription Population, 2000-2015

Figure 42: Global Hypertension Therapeutics Market, Forecasts for Usage Patterns, 2000-2015

Figure 43: Global Dyslipidemia Therapeutics Market, Revenue Forecasts ($bn), 2000-2015

Figure 44: Global Dyslipidemia Therapeutics Market, Average Cost of Therapy ($), 2000-2015

Figure 45: Global Dyslipidemia Therapeutics Market, Volume, 2000-2015

Figure 46: Global Dyslipidemia Therapeutics Market, Forecasts for Diseased Population, 2000-2015

Figure 47: Global Dyslipidemia Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015

Figure 48: Global Dyslipidemia Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015

Figure 49: Global Dyslipidemia Therapeutics Market, Forecasts for Prescription Population, 2000-2015

Figure 50: Global Cardiovascular Therapeutics Market, Forecasts for Treatment Patterns, 2000-2015

Figure 51: Global Thrombosis Therapeutics Market, Revenue Forecasts ($bn), 2000-2015

Figure 52: Global Thrombosis Therapeutics Market, Volume, 2000-2015

Figure 53: Global Thrombosis Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2000-2015

Figure 54: Global Thrombosis Therapeutics Market, Forecasts for Diseased Population, 2000-2015

Figure 55: Global Thrombosis Therapeutics Market, Forecasts for Treatment Seeking Population, 2000-2015

Figure 56: Global Thrombosis Therapeutics Market, Forecasts for Diagnosis Population, 2000-2015

Figure 57: Global Thrombosis Therapeutics Market, Forecasts for Prescription Population, 2000-2015

Figure 58: Global Thrombosis Therapeutics Market, Forecasts for Treatment Patterns, 2000-2015

Figure 59: Global Cardiovascular Disease Therapeutics Market, Market Indicators, 2008

Figure 60: Global Cardiovascular Therapeutics Market, Analysis of Unmet Needs for Major Disease Sectors, 2008

Figure 61: Global Cardiovascular Disease Therapeutics Market, Key Market Events, 2008-2015

Figure 62: Global Cardiovascular Therapeutics Market, Market Share of Top Manufacturers, 2008

Figure 63: Global Cardiovascular Therapeutics Market, Benchmarking Analysis for Top Four Manufacturers, 2008

Figure 64: Global Cardiovascular Therapeutics Market, Benchmarking Analysis for Top Four Manufacturers (Cont..), 2008

Figure 65: Global Cardiovascular Therapeutics Market, M&A Deals by Geography, 2008

Figure 66: Global Cardiovascular Therapeutics Market, M&A Deals by Deal Size, 2008

Figure 67: Global Cardiovascular Therapeutics Market, M&A Deals by Phase, 2008

Figure 68: Global Cardiovascular Therapeutics Market, Top Three M&A Deals, 2008

Figure 69: Global Cardiovascular Therapeutics Market, Licensing Agreement by Geography, 2008

Figure 70: Global Cardiovascular Therapeutics Market, Licensing Agreement by Deal Size, 2008

Figure 71: Global Cardiovascular Therapeutics Market, Licensing Agreements by Phase of Development, 2008

Figure 72: Global Cardiovascular Therapeutics Market, Licensing Agreement by Indications, 2008

Figure 73: GBI Research Methodology

Figure 74: Global Oncology Therapeutics Market Forecasting Model

Companies mentioned

Sanofi-Aventis

Novartis

To order this report:

Cardiovascular Devices Industry: The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

More Market Research Report


    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
2. Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries)
3. Reportlinker Adds Japanese Market for Dental Implants and Final Abutments 2009
4. Reportlinker Adds Japanese Market for Womens Health Devices 2009
5. Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends)
6. Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications
7. Reportlinker Adds Sterilization Technologies: The U.S. Market
8. Reportlinker Adds Renal Disease Treatments: Products and Therapies
9. Reportlinker Adds Kinase Inhibitors: Global Markets
10. Reportlinker Adds Point of Care Diagnostics
11. Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
(Date:12/4/2016)... CA (PRWEB) , ... December 04, 2016 , ... ... without undergoing major cosmetic surgery can now take advantage of a cosmetic procedure ... advanced skin rejuvenation treatment that reduces the appearance of age spots, fine ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders ... American Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in ... , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... across the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF Dothan-Wiregrass ... will help provide scholarship funds for area students and operating support to UNCF-member ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame ... (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking ... prescription drug plan (Part D) need to make changes during this period order for ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, ein Weltführer ... bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific Corporation ... agreement to acquire certain manufacturing assets and capabilities of ... NVC) advanced biological tissue business, as well as a ... $75 million in cash. The Neovasc advanced biological tissue ... the Boston Scientific Lotus™ Valve System. * Upon ...
(Date:12/2/2016)... 2016 Lianluo Smart Limited (Nasdaq: ... which develops, markets and sells medical devices and ... and international markets, recently attended the ... New Progress Forum, co-hosted by the Institute of ... , Guangdong Provincial People,s Hospital and Cardiology Department ...
Breaking Medicine Technology: